Lymphoma Clinical Trials in Colorado

Showing 481-500 of 561 trials

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

NCT00051701

The purpose of this study is to determine the optimal dose of Campath for patients with relapsing or refractory (failed standard therapy) non-Hodgkin's lymphoma. The study will also evaluate the safety of the drug and whether it is effective in treating these patients.

Non-Hodgkins Lymphoma

Genzyme, a Sanofi Company61 participantsStarted Dec 2002

Aurora, Colorado, United States • Colorado Springs, Colorado, United States • Denver, Colorado, United States +14 more locations

TERMINATEDPhase 350 miles

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

NCT00060671

The purpose of this study is to determine whether combining pixantrone (BBR 2778, INN name pending) with the monoclonal antibody rituximab, leads to an increase in the period of patients' remission, compared to rituximab alone.

Lymphoma, FollicularLymphoma, Mixed-Cell, FollicularLymphoma, Small Cleaved-Cell, Follicular+1 more

CTI BioPharma800 participantsStarted Jan 2005

Tucson, Arizona, United States • Greenbrae, California, United States • Los Angeles, California, United States +35 more locations

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

Lymphoma Trials in Other Cities

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

Imexon for Relapsed Follicular and Aggressive Lymphomas

A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

Other Conditions in Colorado